Last reviewed · How we verify
tolvaptan+torasemide
tolvaptan+torasemide is a Combination diuretic (vasopressin V2 receptor antagonist + loop diuretic) Small molecule drug developed by Shanghai Chest Hospital. It is currently FDA-approved for Decompensated heart failure with fluid overload, Cirrhotic ascites and edema.
Tolvaptan blocks vasopressin V2 receptors to promote water excretion, while torasemide inhibits the Na-K-Cl cotransporter in the loop of Henle to increase sodium and water loss.
Tolvaptan, a vasopressin V2 receptor antagonist, is used in combination with torasemide for the treatment of heart failure, including right heart failure and tricuspid regurgitation. The combination of tolvaptan and torasemide has been studied in clinical trials for its safety and efficacy in these conditions.
At a glance
| Generic name | tolvaptan+torasemide |
|---|---|
| Sponsor | Shanghai Chest Hospital |
| Drug class | Combination diuretic (vasopressin V2 receptor antagonist + loop diuretic) |
| Target | Vasopressin V2 receptor (tolvaptan); Na-K-Cl cotransporter (torasemide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Hepatology |
| Phase | FDA-approved |
Mechanism of action
This combination leverages two complementary diuretic mechanisms: tolvaptan is an aquaretic that selectively increases free water clearance without significant electrolyte loss, while torasemide is a loop diuretic that increases overall fluid excretion. Together, they provide enhanced diuresis for conditions requiring aggressive fluid management, such as decompensated heart failure or cirrhotic ascites, with potentially better electrolyte balance than loop diuretics alone.
Approved indications
- Decompensated heart failure with fluid overload
- Cirrhotic ascites and edema
Common side effects
- Hypernatremia
- Hypokalemia
- Hypotension
- Thirst
- Polyuria
Key clinical trials
- The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement (PHASE4)
- The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tolvaptan+torasemide CI brief — competitive landscape report
- tolvaptan+torasemide updates RSS · CI watch RSS
- Shanghai Chest Hospital portfolio CI
Frequently asked questions about tolvaptan+torasemide
What is tolvaptan+torasemide?
How does tolvaptan+torasemide work?
What is tolvaptan+torasemide used for?
Who makes tolvaptan+torasemide?
What drug class is tolvaptan+torasemide in?
What development phase is tolvaptan+torasemide in?
What are the side effects of tolvaptan+torasemide?
What does tolvaptan+torasemide target?
Related
- Drug class: All Combination diuretic (vasopressin V2 receptor antagonist + loop diuretic) drugs
- Target: All drugs targeting Vasopressin V2 receptor (tolvaptan); Na-K-Cl cotransporter (torasemide)
- Manufacturer: Shanghai Chest Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular / Hepatology
- Indication: Drugs for Decompensated heart failure with fluid overload
- Indication: Drugs for Cirrhotic ascites and edema
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing